Abbott E-Mails Could Affect Patent Evergreening Suits

Law360, New York (January 3, 2007, 12:00 AM EST) -- While efforts by pharmaceutical companies to protect market share have always drawn the scrutiny of regulators, recently uncovered documents from Abbott Laboratories have cast a new light on some of these questionable tactics.

A series of e-mails obtained by the Wall Street Journal has revealed the extent to which some companies go to increase sales of their drugs. In the e-mails, Abbott executives discuss how to protect the company’s blockbuster AIDS drug Kaletra in an increasingly competitive marketplace.

The company considered several options, all of which...
To view the full article, register now.